Filter
41
Featured
Language
Document type
No document type
25
Guidelines
9
Fact sheets
4
Manuals
1
Studies & Reports
1
Strategic & Response Plan
1
Countries / Regions
Kenya
1
El Salvador
1
Africa
1
Germany
1
India
1
Authors & Publishers
International Union Against Tuberculosis and Lung Disease, World Health Organization
10
World Health Organization WHO
7
et. al
2
Stephen M. Graham
2
USAID, l'Union, Initiative 5%
2
World Health Organization
2
World Health Organization WHO, Stop TB
2
Alabí Montoya, F.J.
1
and S. Mauder
1
Centers for Disease Control and Prevention
1
Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI) e.V.
1
Dr. Стивена Грэхема, Dr. Малгосии Грземска, Dr. Сюзанны Хилл et al.
1
European centre for disease prevention and control
1
Feiterna- Sperling, C., F. Brinkmann, C. Adamzik, et al.
1
G.H. Wills, E. Wobudeya, et al.
1
Global Drug Facility
1
Graham, S.M.et al.
1
Hindawi Publishing Corporation
1
International Union Against Tuberculosis and Lung Disease
1
J. J. C. Nuttal, B. S. Eley
1
L. N. Patel,and A. K. Detjen
1
Medical Research Council Clinical Trials Unit (MRC CTU) at UCL
1
Mèdecines sans Frontières MSF
1
Médecins sans Frontières MSF
1
Ministerio de Salud El Salvador
1
National Tuberculosis Center
1
New Jersey Medical School
1
Organisation mondiale de la Santé
1
Reijer, P.
1
Republic of Kenya, Ministry of Health
1
SHINE
1
Stop TB Partnership
1
TB Alliance
1
The Union
1
Turkova, A.
1
Unitaid
1
WHO
1
World Health Organisation (WHO)
1
Publication Years
Category
Clinical Guidelines
12
Countries
2
Women & Child Health
1
Key Resources
1
Toolboxes
The Roadmap towards ending TB among children and adolescents, third edition builds on the 2013 and 2018 versions. The 2023 version recognizes the progress made over the past five years and outlines priorities and key actions designed to accelerate progress towards the targets elaborated during the 2... more
N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535 Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)
The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more
This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child... more
This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child... more
MEDBOX Issue Brief no. 19: World TB Day: Invest to end TB. Save Lives
The practical guidance in the operational handbook aims to inform the development or revision of national policies and related implementation guidance on the management of TB in children and adolescents under programmatic circumstances and at different levels of the health system. The operational ha... more
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delama... more

Shorter treatment for children with minimal TB

SHINE Medical Research Council Clinical Trials Unit (MRC CTU) at UCL (2022) CC
The results of the SHINE trial have been published in the NEJM today. SHINE looked at whether treatment for children with minimal TB could be reduced from 6 months to 4 months. It found that the four month treatment was as good as the standard six months treatment for children with minimal TB
Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB drugs and diagnostics to the world
This rapid communication outlines the main outcomes of a WHO convened Guideline Development Group (GDG) meeting, held in May-June 2021 on the topic of the management of TB in children and adolescents. The rapid communication aims to inform staff from ministries of health and care providers across p... more
Clinical guideline for paediatric care of tuberculosis and TB-HIV co-infection

Medicines Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Consensus -based guidelines for diagnosis, prevention and treatment of tuberculosis in children and adolescents
Accessed November 2017
Accessed November 2017
Public Health Action PHA 2017; 7(2): 110–115